OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Summary
This lecture will describe the origin of the production of recombinant bioconjugate vaccines and recent developments in the technology
(for recent review see pubmed.ncbi.nlm.nih.gov/40733680)
I will describe the development of bioconjugation for the low-cost production of glycoconjugate vaccines in three areas; (i) against pathogens where no current vaccine exists (eg Group A Streptococcus), (ii) improving existing glycoconjugate vaccines (eg pneumococcal vaccine), and (iii) affordable glycoconjugate vaccines for the veterinary market (eg poultry). I will speculate on the production of low-cost bioconjugate vaccines in Low- and Middle-income countries including Campylobacter, S. pneumoniae and Group A Streptococcus
Bio
Brendan Wren moved to the LSHTM from St Bartholomew’s Hospital, London in 1999. He is currently Co-Director of the LSHTM Vaccine Centre and Co-Director of GlycoCell, a consortium for the efficient expression of glycan products in bacterial cells for improved vaccines. He has authored over 450 scientific peer-reviewed publications.
Current research focuses on glycosylation in bacterial pathogens and developing a “glycotoolbox” for glycoengineering. The major application of this technology is the construction and production of affordable recombinant glycoconjugate vaccines.
